October 13, 2020
First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
September 30, 2020
Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release
September 30, 2020
Biophytis announces a € 10 million capital increase through private placement. Read the Press Release
September 30, 2020
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
September 18, 2020
Biophytis Reports H1 2020 Financial Results and Provides Business Update. Read the Press Release
September 14, 2020
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
SEPTEMBER 8, 2020
Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences: The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference) The HTID (Health Tech Innovation Days): October 5th & 6th, Paris Bio Europe Fall : October 26-29th (Virtual Conference)
SEPTEMBER 1ST, 2020
Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
August 28, 2020
Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release
AUGUST 4, 2020
Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release